Last reviewed · How we verify
AK-105
At a glance
| Generic name | AK-105 |
|---|---|
| Sponsor | Akesobio Australia Pty Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (PHASE1)
- A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC (PHASE2)
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (PHASE2)
- Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors (PHASE1)
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma (PHASE2)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK-105 CI brief — competitive landscape report
- AK-105 updates RSS · CI watch RSS
- Akesobio Australia Pty Ltd portfolio CI